{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:17:09Z","timestamp":1788250629507,"version":"build-2803163510"},"reference-count":29,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Background: Post-herpetic neuralgia (PHN) is a common refractory complication of herpes zoster, characterized by persistent neuropathic pain that seriously impairs patients\u2019 quality of life. Objectives: The study aimed to assess the clinical effects of gabapentin when administered in combination with Hegu-point catgut embedding in patients suffering from post-herpetic neuralgia (PHN). Methods: A randomized, assessor-blinded study was conducted, wherein a total of 210 PHN patients were equally divided into two groups: 1) the control group receiving only gabapentin and 2) the combination group that received combined therapy of gabapentin and Hegu-point catgut embedding weekly. After 4 weeks of treatment, pain intensity, sleep quality, serum biomarkers, clinical efficacy and adverse events were evaluated. Results: After 4 weeks, both groups displayed a significant reduction in Visual Analogue Scale (VAS) and Pittsburgh Sleep Quality Index (PSQI) scores, with greater improvement reported in the combination group (P &lt; 0.05). In addition, both groups showed a significant decrease in serum levels of substance P, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-?), while ?-endorphin levels showed a significant increase. The changes were found to be more pronounced in the combination group (P &lt; 0.05). Interestingly, the combination group demonstrated a higher overall response rate (92.38% vs 80.00%) and fewer adverse events (12.38% vs 26.67%, P &lt; 0.05). Conclusion: Altogether, combination therapy provided superior short-term improvement in symptoms and biomarker modulation as compared to gabapentin alone. Since the present study only assessed peripheral serum markers, the underlying mechanistic pathways could not be deciphered. Additionally, longer-term outcomes of therapy were not assessed, serving as a major limitation of this study.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.5.152.1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:13:33Z","timestamp":1775304813000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamic Basis Of Gabapentin Combined With Hegu-Point Catgut Embedding For Post-Herpetic Neuralgia"],"prefix":"10.36721","author":[{"given":"Li-Ping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Abd-Elsalam WH, Al-Mahallawi AM and Makhlouf A (2024). Relieving postherpetic neuralgia pain via gabapentin-loaded bigels as an auspicious topical drug delivery system. Daru., 32(2): 705-714.","DOI":"10.1007\/s40199-024-00541-y"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Daryaee F and Tonge PJ (2019). Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics. Curr. Opin. Chem Biol., 50:120-127.","DOI":"10.1016\/j.cbpa.2019.03.008"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A and Shabestan R (2020).  Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean. J. Pain., 33: 3-12.","DOI":"10.3344\/kjp.2020.33.1.3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"De Stefano G, Di Pietro G, Truini A, Cruccu G and Di Stefano G (2023). Considerations when using gabapentinoids to treat trigeminal Neuralgia: A review. Neuropsychiatr. Dis. Treat., 19: 2007-2012.","DOI":"10.2147\/NDT.S407543"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Domon Y, Kobayashi N, Kubota K, Kitano Y, Ueki H, Shimojo Y, Ishikawa K and Ofune Y (2023). The novel gabapentinoid mirogabalin prevents upregulation of \u03b12\u03b4-1 subunit of voltage-gated calcium channels in spinal dorsal horn in a rat model of spinal nerve ligation. Drug. Res (Stuttg)., 73(1): 54-60.","DOI":"10.1055\/a-1941-8907"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Evoy KE, Peckham AM, Covvey JR and Tidgewell KJ (2021). Gabapentinoid pharmacology in the context of emerging misuse liability. J. Clin. Pharmacol., 61(Suppl 2): S89-s99.","DOI":"10.1002\/jcph.1833"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fernandez-Vial D, Sangalli L and Perez C (2022). A rare case of idiopathic painful nervus intermedius neuropathy in a 13-year-old female: A case report and discussion in the context of the literature. Children., 9(8): 1234.","DOI":"10.3390\/children9081234"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gao Z, Cui M, Zhang J and Ji L (2022). Activation likelihood estimation identifies brain regions activated during puncturing at Hegu in healthy volunteers: A meta-analysis. Front. Neurosci.,16:1084362.","DOI":"10.3389\/fnins.2022.1084362"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gold JR, Grubb TL, Cox S, Malavasi L and Villarino NL (2022). Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses. J. Vet. Intern Med., 36(2): 792-797.","DOI":"10.1111\/jvim.16386"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"G Gyeltshen D, Dorji T, Tenzin K, Choeda T, Gurung MS, Pongpirul K and Jing L (2025). Efficacy and safety of warm acupuncture compared to gabapentin for pain management in patients with sciatica in Bhutan: A randomized controlled (ACUWARM) Trial. J. Evid. Based Integr Med., 30: 2515690-251355513.","DOI":"10.1177\/2515690X251355513"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kaye AD, Cassagne G, Abbott BM, Dubuisson AM, Fagan JJ, Indovina I, Gungor D, Kallurkar A, Kaye AM and Shekoohi S (2025). Emerging clinical roles of gabapentin and adverse effects, including weight gain, obesity, depression, suicidal thoughts and increased risk of opioid-related overdose and respiratory depression: A narrative review. Curr. Pain. Headache. Rep., 29(1): 95.","DOI":"10.1007\/s11916-025-01410-2"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger J and Lerche H (2024). Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant. Neuropharmacology., 250: 109892.","DOI":"10.1016\/j.neuropharm.2024.109892"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lambarth A, Zarate-Lopez N and Fayaz A (2022). Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol. Motil., 34(1): e14289.","DOI":"10.1111\/nmo.14289"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Masciullo M, Pichiorri F, Scivoletto G, Foti C and Molinari M (2021). Flumazenil therapy for a gabapentin-induced coma: a case report. J. Med. Case. Rep., 15(1): 242.","DOI":"10.1186\/s13256-021-02816-3"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Meaadi J, Obara I, Eldabe S and Nazar H (2023). The safety and efficacy of gabapentinoids in the management of neuropathic pain: A systematic review with meta-analysis of randomised controlled trials. Int. J. Clin. Pharm., 45(3): 556-565.","DOI":"10.1007\/s11096-022-01528-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Menaldi SL, Halim PA and Kurniawan K (2022). Efficacy of gabapentinoids for acute herpes zoster in preventing postherpetic neuralgia: A systematic review of randomized controlled trials. Dermatol. Online. J., 28(5).","DOI":"10.5070\/D328559238"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Miyoshi T, Mizushima C, Noborio Y, Kimoto Y, Nakaharu Y and Shimamoto S (2021). Efficacy of combination therapy with gabapentin and guanfacine for paroxysmal sympathetic hyperactivity following hypoxic encephalopathy: A case report. J. Int. Med. Res., 49(4): 3000605211009721.","DOI":"10.1177\/03000605211009721"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mu J, Furlan AD, Lam WY, Hsu MY, Ning Z and Lao L (2020). Acupuncture for chronic nonspecific low back pain. Cochrane. Database. Syst. Rev., 12(12): Cd013814.","DOI":"10.1002\/14651858.CD013814"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Nakamura S, Komatsu S, Yamada T, Kitahara H and Yamamoto T (2023). Oral morphine induces spinal 5-hydroxytryptamine (5-HT) release using an opioid receptor-independent mechanism. Pharmacol. Res. Perspect., 11(4): e01119.","DOI":"10.1002\/prp2.1119"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Oggianu L, Garrone B, Fiorentini F, Del Bene F, Rosignoli MT, Di Giorgio FP and Kaminski RM (2023). PK\/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK-PD modeling from nonclinical to clinical development. Clin. Transl. Sci., 16(4): 606-617.","DOI":"10.1111\/cts.13472"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pan L, Zeng X and Wang G (2024). Early treatment with electroacupuncture at Jiaji acupoints reduce the incidence of postherpetic neuralgia. Asian. J. Surg., 47(7): 3288-3289.","DOI":"10.1016\/j.asjsur.2024.03.152"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Papassidero P, Wichert-Ana L, Lia EN, Alexandre-Santos L, Trevisan AC, Coelho EB, Della Pasqua O, Lanchote VL and Dach F (2023). Pharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: A [99mTc]Tc-ECD SPECT study. Reg. Anesth. Pain. Med., 48(8): 408-413.","DOI":"10.1136\/rapm-2022-104047"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Rusciano D (2024). Molecular mechanisms and therapeutic potential of gabapentin with a focus on topical formulations to treat ocular surface diseases. Pharmaceuticals. (Basel)., 17(5): 623.","DOI":"10.3390\/ph17050623"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Shi Y and Song C (2024). Effectiveness and safety of gabapentin versus pregabalin in the treatment of postherpetic neuralgia: A retrospective cohort study. Br. J. Hosp. Med. (Lond)., 85(12): 1-11.","DOI":"10.12968\/hmed.2024.0485"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wang JL, Li HL, Liu XB, Zhao JG, Huang D, Wu C, Wang JS and Chen J (2025). Efficacy and safety of ozone injection into the intervertebral foramen for treating patients with chronic, intractable postherpetic neuralgia: A one-year follow-up study. Front. Neurol., 16: 1602689.","DOI":"10.3389\/fneur.2025.1602689"},{"key":"ref25","unstructured":"Wang L, Qiu L, Zheng X, Ouyang J, Zhang M, He L, Zeng S, Liu B and Peng J (2020). Effectiveness of electroacupuncture at Jiaji acupoints (EX-B2), plus moxibustion and intermediate on postherpetic neuralgia: A randomized controlled trial. J. Tradit. Chin. Med., 40(1): 121-127."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zamora-Diaz IY, Gonzalez-Trujano ME, Martinez-Vargas D, Moreno-Perez GF, Hernandez-Leon A, Narvaez-Gonzalez HF, Ventura-Mart\u00ednez R, Pellicer F and Lopez-Munoz FJ (2025). Pharmacological interactions of sulforaphane and gabapentin in a murine fibromyalgia-like pain model. Biomed. Pharmacother., 184: 117929.","DOI":"10.1016\/j.biopha.2025.117929"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zhang YH, Hu HY, Xiong YC, Peng C, Hu L, Kong YZ, Wang YL, Guo JB, Bi S, Li TS, Ao LJ, Wang CH, Bai YL, Fang L, Ma C, Liao LR, Liu H, Zhu Y, Zhang ZJ, Liu CL, Fang GE and Wang XQ (2021). Exercise for neuropathic pain: A systematic review and expert consensus. Front. Med. (Lausanne)., 8: 756940.","DOI":"10.3389\/fmed.2021.756940"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Zhou Q, Wei S, Zhu H, Hu Y, Liu Y, Yang H, Zeng S, Chai S, Li J and Tao M (2021). Acupuncture and moxibustion combined with cupping for the treatment of post-herpetic neuralgia: A meta-analysis. Medicine. (Baltimore)., 100(31): e26785.","DOI":"10.1097\/MD.0000000000026785"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:49:52Z","timestamp":1788248992000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.5.152.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}